TY - JOUR
T1 - Preoperative Versus Postoperative Fractionated Stereotactic Radiation Therapy
T2 - A Single Institution Analysis of 534 Resected Metastases
AU - Perlow, Haley K.
AU - Hennings, Sarah
AU - Bradshaw, Jared
AU - Reddy, Sohil
AU - Luu, Sydney
AU - Matsui, Jennifer K.
AU - Klamer, Brett G.
AU - Dibs, Khaled
AU - Harrell, Marshall
AU - McGregor, John M.
AU - Lonser, Russell R.
AU - Prevedello, Daniel M.
AU - Elder, James B.
AU - Wu, Kyle C.
AU - Prabhu, Roshan
AU - Zhu, Simeng
AU - Singh, Raj
AU - Beyer, Sasha J.
AU - Grecula, John
AU - Blakaj, Dukagjin M.
AU - Thomas, Evan M.
AU - Raval, Raju R.
AU - Palmer, Joshua D.
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025
Y1 - 2025
N2 - Purpose: Patients with large or symptomatic brain metastases typically have surgery followed by postoperative (post-op) stereotactic radiosurgery. However, post-op stereotactic radiosurgery leads to elevated rates of radiation necrosis (RN), nodular meningeal disease (nMD), and local failure (LF) when compared with whole brain radiation therapy. Fractionated stereotactic radiation therapy (FSRT) can deliver a higher biological effective dose and may reduce the risk of LF, and preoperative (pre-op) treatments may reduce the risk of RN and nMD through treating smaller volumes and tumor sterilization. Methods and Materials: This single institution cohort study included patients who had surgical resection and FSRT to at least one brain metastasis. Pre-op or post-op FSRT was delivered with a dose of 27 Gy in 3 fractions or 30 Gy in 5 fractions. The primary endpoint was a composite endpoint defined by (1) LF, (2) nMD, and/or (3) grade 2 or higher (symptomatic) RN. Results: Of the 534 resected brain metastases from 458 patients were eligible for analysis, 235 and 299 metastases received pre-op and post-op FSRT, respectively. Notably, 4 (1.7%) pre-op and 14 (4.7%) post-op metastases were diagnosed with nMD (P = .088). Notably, 28 (12%) and 59 (20%) metastases that received pre-op and post-op FSRT, respectively, experienced the composite endpoint (P = .018). The 3-year composite endpoint for pre-op and post-op FSRT was 15% (95% CI, 10%-20%) and 20% (95% CI, 15%-25%), respectively. Conclusions: In our study, pre-op FSRT compares favorably to post-op FSRT primarily because of a lower incidence of nMD. Differences between treatment groups for symptomatic RN or LF endpoints were comparatively smaller. Prospective validation of pre-op FSRT is needed.
AB - Purpose: Patients with large or symptomatic brain metastases typically have surgery followed by postoperative (post-op) stereotactic radiosurgery. However, post-op stereotactic radiosurgery leads to elevated rates of radiation necrosis (RN), nodular meningeal disease (nMD), and local failure (LF) when compared with whole brain radiation therapy. Fractionated stereotactic radiation therapy (FSRT) can deliver a higher biological effective dose and may reduce the risk of LF, and preoperative (pre-op) treatments may reduce the risk of RN and nMD through treating smaller volumes and tumor sterilization. Methods and Materials: This single institution cohort study included patients who had surgical resection and FSRT to at least one brain metastasis. Pre-op or post-op FSRT was delivered with a dose of 27 Gy in 3 fractions or 30 Gy in 5 fractions. The primary endpoint was a composite endpoint defined by (1) LF, (2) nMD, and/or (3) grade 2 or higher (symptomatic) RN. Results: Of the 534 resected brain metastases from 458 patients were eligible for analysis, 235 and 299 metastases received pre-op and post-op FSRT, respectively. Notably, 4 (1.7%) pre-op and 14 (4.7%) post-op metastases were diagnosed with nMD (P = .088). Notably, 28 (12%) and 59 (20%) metastases that received pre-op and post-op FSRT, respectively, experienced the composite endpoint (P = .018). The 3-year composite endpoint for pre-op and post-op FSRT was 15% (95% CI, 10%-20%) and 20% (95% CI, 15%-25%), respectively. Conclusions: In our study, pre-op FSRT compares favorably to post-op FSRT primarily because of a lower incidence of nMD. Differences between treatment groups for symptomatic RN or LF endpoints were comparatively smaller. Prospective validation of pre-op FSRT is needed.
UR - https://www.scopus.com/pages/publications/105015480439
U2 - 10.1016/j.ijrobp.2025.08.010
DO - 10.1016/j.ijrobp.2025.08.010
M3 - Article
C2 - 40825402
AN - SCOPUS:105015480439
SN - 0360-3016
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
ER -